Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob P Lalezari

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 18, 2001
High dose oral ganciclovir treatment for cytomegalovirus retinitisJacob P Lalezari, Dorothy N Friedberg, Jack Bissett, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson, Jacob P Lalezari, Melanie A Thompson, et al.
AIDS (London, England)|March 21, 2003
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyJacob P Lalezari, Joseph J Eron, Margrit Carlson, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
The Journal of Infectious Diseases|March 5, 2005
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimenJacob P Lalezari, Nicholaos C Bellos, Kunthavi Sathasivam, et al.
AIDS Research and Human Retroviruses|August 9, 2002
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adultsJ Michael Kilby, Jacob P Lalezari, Joseph J Eron, et al.
Contemporary Clinical Trials|November 11, 2025
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIVAna Gabriela Pires Dos Santos, Manal Abunimeh, Beatriz Mothe, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 19, 2008
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapyRichard T Davey, Peter E Pertel, Alice Benson, et al.
The Lancet. HIV|October 2, 2015
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trialJacob P Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 18, 2001
High dose oral ganciclovir treatment for cytomegalovirus retinitisJacob P Lalezari, Dorothy N Friedberg, Jack Bissett, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson, Jacob P Lalezari, Melanie A Thompson, et al.
AIDS (London, England)|March 21, 2003
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyJacob P Lalezari, Joseph J Eron, Margrit Carlson, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
The Journal of Infectious Diseases|March 5, 2005
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimenJacob P Lalezari, Nicholaos C Bellos, Kunthavi Sathasivam, et al.
AIDS Research and Human Retroviruses|August 9, 2002
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adultsJ Michael Kilby, Jacob P Lalezari, Joseph J Eron, et al.
Contemporary Clinical Trials|November 11, 2025
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIVAna Gabriela Pires Dos Santos, Manal Abunimeh, Beatriz Mothe, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 19, 2008
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapyRichard T Davey, Peter E Pertel, Alice Benson, et al.
The Lancet. HIV|October 2, 2015
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trialJacob P Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Pageof 4